DK1583529T3 - Aminosyre-phenoxy-ethere, fremstilling og anvendelse deraf - Google Patents

Aminosyre-phenoxy-ethere, fremstilling og anvendelse deraf

Info

Publication number: DK1583529T3
Authority: DK; Denmark
Prior art keywords: amino acid; preparation; acid phenoxy; phenoxy ethers; ethers
Prior art date: 2003-01-17

Application number

DK04701752.0T

Other languages

English (en)

Inventor

Bishwajit Nag

Abhijeet Nag

Debendranath Dey

Shiv Kumar Agarwal

Original Assignee

Bexel Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-01-17

Filing date

2004-01-13

Publication date

2012-01-23

2004-01-13 Application filed by Bexel Pharmaceuticals Inc filed Critical Bexel Pharmaceuticals Inc

2012-01-23 Application granted granted Critical

2012-01-23 Publication of DK1583529T3 publication Critical patent/DK1583529T3/da

Links

-1 Amino acid phenoxy ethers Chemical class 0.000 title abstract 2
208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
208000012902 Nervous system disease Diseases 0.000 abstract 1
208000025966 Neurological disease Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
208000026278 immune system disease Diseases 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/44—Two oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Immunology (AREA)
Obesity (AREA)
Hematology (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

DK04701752.0T 2003-01-17 2004-01-13 Aminosyre-phenoxy-ethere, fremstilling og anvendelse deraf DK1583529T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US44077203P	2003-01-17	2003-01-17
US10/356,113 US6794401B2 (en)	2003-01-17	2003-01-31	Amino acid phenoxy ethers
PCT/US2004/000790 WO2004066964A2 (en)	2003-01-17	2004-01-13	Amino acid phenoxy ethers

Publications (1)

Publication Number	Publication Date
DK1583529T3 true DK1583529T3 (da)	2012-01-23

Family

ID=32716922

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04701752.0T DK1583529T3 (da)	2003-01-17	2004-01-13	Aminosyre-phenoxy-ethere, fremstilling og anvendelse deraf

Country Status (20)

Country	Link
US (2)	US6794401B2 (da)
EP (1)	EP1583529B9 (da)
JP (1)	JP4833072B2 (da)
KR (1)	KR101085315B1 (da)
AT (1)	ATE532510T1 (da)
AU (1)	AU2004207449A1 (da)
BR (1)	BRPI0406772B1 (da)
CA (1)	CA2513496C (da)
CY (1)	CY1112673T1 (da)
DK (1)	DK1583529T3 (da)
EA (1)	EA200501078A1 (da)
ES (1)	ES2374724T3 (da)
MA (1)	MA27658A1 (da)
MX (1)	MXPA05007684A (da)
NO (1)	NO330984B1 (da)
NZ (1)	NZ541328A (da)
PT (1)	PT1583529E (da)
SI (1)	SI1583529T1 (da)
TW (1)	TWI325420B (da)
WO (1)	WO2004066964A2 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7521465B2 (en) *	2003-01-17	2009-04-21	Bexel Pharmaceuticals, Inc.	Diphenyl ether derivatives
US7781464B2 (en) *	2003-01-17	2010-08-24	Bexel Pharmaceuticals, Inc.	Heterocyclic diphenyl ethers
US7087576B2 (en) *	2003-10-07	2006-08-08	Bexel Pharmaceuticals, Inc.	Dipeptide phenyl ethers
US7592486B2 (en) *	2004-09-16	2009-09-22	Board Of Regents Of The University Of Nebraska	Anhydrous fluoride salts and reagents and methods for their production
EP1858845A2 (en) *	2005-03-18	2007-11-28	Orchid Chemicals and Pharmaceuticals Limited	Novel tyrosine derivatives
US20090203744A1 (en) *	2005-07-29	2009-08-13	Pande Y Surendrakumar Satyanarayan	Novel pyridine derivatives
EP2066800A2 (en) *	2006-08-04	2009-06-10	Decode Genetics EHF	Aryl amino acid derivatives as inhibitors of lta4h (leukotriene a4 hydrolase) for treating inflammation
EP2170306A1 (en) *	2007-06-26	2010-04-07	Lexicon Pharmaceuticals, Inc.	Methods of treating serotonin-mediated diseases and disorders
US7875622B2 (en)	2007-07-11	2011-01-25	Lexicon Pharmaceuticals, Inc.	Methods and compositions for treating pulmonary hypertension and related diseases and disorders
WO2009030968A1 (en) *	2007-09-05	2009-03-12	Orchid Research Laboratories Limited	Mao a inhibitors with a diphenyl ether-substructure.
WO2009143041A1 (en)	2008-05-20	2009-11-26	Merck & Co., Inc.	Efficient production of heterologous proteins using mannosyl transferase inhibitors
CN103108634B (zh)	2010-07-28	2015-08-12	幽兰化学医药有限公司	用于治疗肝病、肺病、糖尿病并发症和心血管疾病的二苯醚化合物
US9056862B2 (en)	2011-05-10	2015-06-16	National University Corporation Kobe University	Thioxothiazolidine derivative having Ras function inhibitory effect

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020049240A1 (en) *	1994-12-19	2002-04-25	Beecham Group P.1.C.	Novel compounds
US5166137A (en)	1991-03-27	1992-11-24	Nobipols Forskningsstiftelse	Guluronic acid polymers and use of same for inhibition of cytokine production
US5441971A (en) *	1991-04-11	1995-08-15	The Upjohn Company	Thiazolidinedione derivatives, production and use thereof
ES2139633T3 (es) *	1992-08-31	2000-02-16	Sankyo Co	Derivados de oxazolidina con propiedades anti-diabetica y anti-obesidad, su preparacion y su utilizacion terapeutica.
TW268952B (da) *	1993-02-26	1996-01-21	Takeda Pharm Industry Co Ltd
NZ274346A (en) *	1993-09-15	1997-06-24	Sankyo Co	Use of various thiazolidine-2,4-dione and oxazolidine-2,4-dione derivatives to prevent or delay onset of non-insulin dependent diabetes mellitus
US5527546A (en)	1994-08-10	1996-06-18	Bayer Corporation	Human interleukin 6 inhibitor
DE4432101A1 (de) *	1994-09-09	1996-03-14	Hoechst Ag	Aminosäure-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
ATE271128T1 (de)	1995-05-11	2004-07-15	Applied Research Systems	Inhibitoren der il-6 aktivitaet
IL118474A (en) *	1995-06-01	2001-08-08	Sankyo Co	Benzimideol derivatives and pharmaceutical preparations containing them
TWI238064B (en) *	1995-06-20	2005-08-21	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
TW577875B (en) *	1997-01-31	2004-03-01	Shionogi & Co	Pyrrolidine derivatives with inhibitory activity for phospholipase A2
JPH11124331A (ja) *	1997-08-21	1999-05-11	Takeda Chem Ind Ltd	抗炎症剤
US6331633B1 (en)	1998-05-08	2001-12-18	Calyx Therapeutics Inc.	Heterocyclic analogs of diphenylethylene compounds
US6699896B1 (en) *	1998-05-12	2004-03-02	Wyeth	Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
WO1999064417A2 (en) *	1998-06-05	1999-12-16	Astrazeneca Ab	Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
US6664281B1 (en) *	1998-08-27	2003-12-16	Ono Pharmaceutical Co., Ltd.	Carboxylic acid derivatives and drugs containing the same as the active ingredient
YU72201A (sh)	1999-04-28	2005-07-19	Aventis Pharma Deutschland Gmbh.	Derivati di-aril kiseline kao ppar receptorski ligandi
TWI284533B (en) *	1999-05-24	2007-08-01	Sankyo Co	Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
KR20010099634A (ko)	1999-07-01	2001-11-09	할리 켈빈 비.	텔로머라제 저해제 및 그 사용 방법
CN1155586C (zh) *	1999-08-23	2004-06-30	杏林制药株式会社	取代的苄基噻唑烷-2,4-二酮衍生物
JP2003508391A (ja) *	1999-08-31	2003-03-04	マキシア・ファーマシューティカルズ・インコーポレイテッド	ベンジリデン−チアゾリジンジオン類およびアナログ類ならびに糖尿病の治療におけるその使用
JP2001199888A (ja) *	2000-01-24	2001-07-24	Fujimoto Brothers:Kk	糖尿病治療剤
JP2001294537A (ja) *	2000-02-10	2001-10-23	Takeda Chem Ind Ltd	併用医薬
EP1148054B1 (en)	2000-04-21	2005-11-23	Pfizer Products Inc.	Thyroid receptor ligands
US6680387B2 (en) *	2000-04-24	2004-01-20	Aryx Therapeutics	Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis

2003
- 2003-01-31 US US10/356,113 patent/US6794401B2/en not_active Expired - Lifetime
2004
- 2004-01-13 KR KR1020057013193A patent/KR101085315B1/ko not_active Expired - Fee Related
- 2004-01-13 EP EP04701752A patent/EP1583529B9/en not_active Expired - Lifetime
- 2004-01-13 ES ES04701752T patent/ES2374724T3/es not_active Expired - Lifetime
- 2004-01-13 JP JP2006536536A patent/JP4833072B2/ja not_active Expired - Fee Related
- 2004-01-13 DK DK04701752.0T patent/DK1583529T3/da active
- 2004-01-13 CA CA2513496A patent/CA2513496C/en not_active Expired - Fee Related
- 2004-01-13 MX MXPA05007684A patent/MXPA05007684A/es active IP Right Grant
- 2004-01-13 PT PT04701752T patent/PT1583529E/pt unknown
- 2004-01-13 NZ NZ541328A patent/NZ541328A/en not_active IP Right Cessation
- 2004-01-13 AT AT04701752T patent/ATE532510T1/de active
- 2004-01-13 EA EA200501078A patent/EA200501078A1/ru unknown
- 2004-01-13 SI SI200431804T patent/SI1583529T1/sl unknown
- 2004-01-13 AU AU2004207449A patent/AU2004207449A1/en not_active Abandoned
- 2004-01-13 BR BRPI0406772A patent/BRPI0406772B1/pt not_active IP Right Cessation
- 2004-01-13 WO PCT/US2004/000790 patent/WO2004066964A2/en not_active Ceased
- 2004-01-14 TW TW093100932A patent/TWI325420B/zh not_active IP Right Cessation
- 2004-09-21 US US10/947,047 patent/US20050096366A1/en not_active Abandoned
2005
- 2005-08-01 NO NO20053714A patent/NO330984B1/no not_active IP Right Cessation
- 2005-08-16 MA MA28444A patent/MA27658A1/fr unknown
2012
- 2012-02-09 CY CY20121100137T patent/CY1112673T1/el unknown

Also Published As

Publication number	Publication date
ATE532510T1 (de)	2011-11-15
WO2004066964A2 (en)	2004-08-12
NO330984B1 (no)	2011-08-29
JP2007501288A (ja)	2007-01-25
TW200418792A (en)	2004-10-01
EP1583529B9 (en)	2012-04-04
MA27658A1 (fr)	2005-12-01
MXPA05007684A (es)	2006-03-10
BRPI0406772B1 (pt)	2016-08-23
NO20053714D0 (no)	2005-08-01
EA200501078A1 (ru)	2006-02-24
NZ541328A (en)	2008-11-28
US20040142991A1 (en)	2004-07-22
WO2004066964A9 (en)	2004-09-02
SI1583529T1 (sl)	2012-02-29
KR20050092764A (ko)	2005-09-22
ES2374724T3 (es)	2012-02-21
JP4833072B2 (ja)	2011-12-07
PT1583529E (pt)	2012-02-13
TWI325420B (en)	2010-06-01
CA2513496C (en)	2013-05-14
EP1583529B1 (en)	2011-11-09
CA2513496A1 (en)	2004-08-12
AU2004207449A1 (en)	2004-08-12
US20050096366A1 (en)	2005-05-05
WO2004066964A3 (en)	2005-02-24
CY1112673T1 (el)	2016-02-10
EP1583529A2 (en)	2005-10-12
NO20053714L (no)	2005-10-11
KR101085315B1 (ko)	2011-11-22
EP1583529A4 (en)	2007-07-04
US6794401B2 (en)	2004-09-21
BRPI0406772A (pt)	2005-12-27

Publication	Publication Date	Title
CY1112673T1 (el)	2016-02-10	Φαινοξυ αιθερες αμινοξεων
DK1651161T3 (da)	2012-01-30	Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
ATE417037T1 (de)	2008-12-15	Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
NO20070782L (no)	2007-04-02	Tetrapeptidanaloger.
EA200800172A1 (ru)	2008-08-29	2,4-диаминопиримидины как ингибиторы aurora
IS7684A (is)	2005-02-03	Ný efnasambönd, blöndur og aðferðir til að meðhöndla bólgusjúkdóma og -ástand
MXPA05010830A (es)	2005-12-15	Metodos de tratamiento que usan agentes de enlace especificos de angiopoyetina-2 humana.
SE0301700D0 (sv)	2003-06-10	Novel compounds
ATE515514T1 (de)	2011-07-15	Verwendungen von säuger-cytokin il-23 ; verwandte reagenzien
UA85559C2 (en)	2009-02-10	Aminobenzophenone compounds
IL159960A (en)	2010-12-30	Indane acetic acid derivatives, pharmaceutical compositions comprising them and uses thereof for the preparation of medicaments
EA200601837A1 (ru)	2007-04-27	Бензоксазины для лечения заболеваний дыхательных путей
PL1622939T3 (pl)	2012-08-31	Aktywne warianty białka wiążącego IL-18 i ich medyczne zastosowania
EA200501821A1 (ru)	2006-06-30	Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
EP2107071A3 (en)	2009-12-30	Anti-EpCAM immunoglobulins
EA200602154A1 (ru)	2007-06-29	Пиридин-4-илэтинилимидазолы и -пиразолы как антагонисты рецептора mglu5
CY1105105T1 (el)	2009-11-04	Χρηση του διστροντιου αλατος του 2-[ν,ν-δι(καρβοξυμεξυλ) amino]- 3-κυανο-4-καρβοξυμεθυλ-θειοφενο-5-καρβοξυλικου οξεος για τη ληψη φαρμακων που προοριζονται για τη θεραπεια γαστρο-δωδεκαδακτυλικων πονων
UA92013C2 (en)	2010-09-27	Novel indoline compounds
ATE392213T1 (de)	2008-05-15	Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
WO2004056762A3 (en)	2004-08-12	Novel aminobenzophenone compounds
EA200500624A1 (ru)	2005-10-27	Промотор для il-18bp, его получение и применение
EA200500903A1 (ru)	2005-12-29	Силиловые простые эфиры
DE502004012439D1 (de)	2011-06-09	Medikament und verwendung zur tumortherapie
WO2005018567A3 (en)	2005-09-29	Compounds and compositions for the treatment of diabetes and diabetes-related disorders
AU2013204147B2 (en)	2015-09-03	Treatment of TNFalpha related disorders